Harmony Biosciences Sees 26.7% EPS Growth Forecast and 10% Cash Flow Rise
Harmony Biosciences’ EPS is projected to grow 26.7% this year, more than double the 13.7% industry average, building on a 13.1% historical growth rate. The company’s year-over-year cash flow rose 10% versus a -3.1% industry average and its current-year earnings estimates have increased by 7.4% in the past month.
1. Earnings Growth Outlook
Harmony Biosciences has delivered a historical EPS growth rate of 13.1% and analysts project EPS to increase 26.7% this year, more than double the 13.7% average within its industry.
2. Cash Flow Expansion
The company's operating cash flow rose 10% year-over-year, contrasting with a -3.1% industry average, and its annualized cash flow growth over the past three to five years stands at 25.7% versus 4.4% for peers.
3. Upward Estimate Revisions
Current-year earnings forecasts for Harmony Biosciences have been revised upward by 7.4% in the last month, indicating growing confidence in its near-term profitability.
4. Growth Rating and Investment Outlook
This combination of accelerated earnings, robust cash flow, and positive estimate revisions supports Harmony Biosciences' high growth rating and positions it for potential outperformance.